Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Hyman, David M., Puzanov, Igor, Subbiah, Vivek, Faris, Jason E., Chau, Ian, Blay, Jean-Yves, Wolf, Jürgen, Raje, Noopur S., Diamond, Eli L., Hollebecque, Antoine, Gervais, Radj, Elez-Fernandez, Maria Elena, Italiano, Antoine, Hofheinz, Ralf-Dieter, Hidalgo, Manuel, Chan, Emily, Schuler, Martin, Lasserre, Susan Frances, Makrutzki, Martina, Sirzen, Florin, Veronese, Maria Luisa, Tabernero, Josep, Baselga, José·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1502309

Cited by (1,002)

Items 701–800 of 1,002

BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities
Aaron Ciner, Yixing Jiang, Petr Frantisek Hausner · 2022 · Molecular Cancer Research
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas
Cindy Neuzillet, Benoît Rousseau, Hemant Mahendrakumar Kocher, Philippe Bourget, Christophe Tournigand · 2017 · Pharmacology & Therapeutics
Recent advances and emerging therapies in anaplastic thyroid carcinoma
Maria E. Cabanillas, Mark Zafereo, Michelle D. Williams, Renata Ferrarotto, Ramona Dadu, Neil D. Gross, G. Brandon Gunn, Heath Devin Skinner, Gilbert J. Cote, Horiana B. Grosu et al. · 2018 · F1000Research
An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy
Milen Minkov · 2018 · Expert Opinion on Pharmacotherapy
PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors
Matthias A. Roelli, Dorothée Ruffieux-Daidié, Amandine Stooss, Oussama ElMokh, Wayne Allen Phillips, Matthias S. Dettmer, Roch‐Philippe Charles · 2017 · Oncotarget
Optimal two-stage designs for exploratory basket trials.
Heng Zhou, Fang Liu, Cai Wu, E. Rubin, V. Giranda, Cong Chen · 2019 · Contemporary Clinical Trials
Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices
Danielle S. Bitterman, Daniel N. Cagney, Lisa Singer, Paul Linh Nguyen, Paul J. Catalano, Raymond H. Mak · 2019 · JNCI Journal of the National Cancer Institute
Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers
Priyanka Gopal, Elif Irem Sarihan, Eui Kyu Chie, Gwendolyn B. Kuzmishin, Semihcan Doken, Nathan A. Pennell, Daniel Philip Raymond, Sudish C. Murthy, Usman Ahmad, Siva Raja et al. · 2019 · Nature Communications
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets
Linde Kehmann, Markus Sebastian Jördens, S.H. Loosen, Tom Luedde, Christoph Roderburg, Catherine Leyh · 2024 · ESMO Open
Lung Adenocarcinoma with Anaplastic Lymphoma Kinase (ALK) Rearrangement Presenting as Carcinoma of Unknown Primary Site: Recognition and Treatment Implications
John Daniel Hainsworth, F. Anthony Greco · 2016 · Drugs - Real World Outcomes
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies
Raghav Sundar, David S. Hong, Scott Kopetz, Timothy Anthony Yap · 2017 · Cancer Discovery
Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations
Annelieke E.C.A.B. Willemsen, Sarah Krausz, Marjolijn J. L. Ligtenberg, Katrien Grünberg, Harry J.M. Groen, Emile E. Voest, Edwin P. J. G. Cuppen, Hanneke W.M. van Laarhoven, Carla M.L. van Herpen · 2019 · British Journal of Cancer
Emerging protein kinase inhibitors for the treatment of multiple myeloma
Judith Lind, Felix Czernilofsky, Sonia Vallet, Klaus Podar · 2019 · Expert Opinion on Emerging Drugs
The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology
Victor T. G. Lin, Eddy Shih-Hsin Yang · 2019 · JNCI Journal of the National Cancer Institute
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
Blessie Elizabeth Nelson, Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing, Sarina Anne Piha-Paul, Siqing Fu, Apostolia Maria Tsimberidou, Maria E. Cabanillas et al. · 2023 · npj Precision Oncology
Novel therapeutics in low-grade serous ovarian cancer
Lauren Patterson Cobb, David Marc Gershenson · 2023 · International Journal of Gynecological Cancer
Somatic mutations in salivary duct carcinoma and potential therapeutic targets
Timothy Khoo, Bing Yu, Joel Anthony Smith, Angus John Clarke, Peter P. Luk, Christina I. Selinger, Kate Lynette Mahon, Spiridoula Kraitsek, Carsten Erich Palme, Michael Joseph Boyer et al. · 2017 · Oncotarget
BRAF-mutant colorectal cancer, a different breed evolving
Eleonora Lai, Andrea Pretta, Valentino Impera, Stefano Mariani, Riccardo Giampieri, Laura Casula, Valeria Pusceddu, Pierpaolo Coni, Daniela Fanni, Marco Puzzoni et al. · 2018 · Expert Review of Molecular Diagnostics
Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment
KATAOKA, MASAHIRO, KITAZAWA, MASATO, NAKAMURA, SATOSHI, KOYAMA, MAKOTO, YAMAMOTO, YUTA, MIYAZAKI, SATORU, HONDO, NAO, TANAKA, HIROKAZU, SOEJIMA, YUJI · 2023 · Anticancer Research
Autophagy sustains mitochondrial respiration and determines resistance to BRAF V600E inhibition in thyroid carcinoma cells
Sergio Díaz Gago, Javier Vicente-Gutiérrez, Jose Manuel Ruiz-Rodríguez, Josep Calafell-Segura, Alicia Álvarez-Álvarez, Marina Lasa, Antonio Chiloeches, Pablo Baquero · 2024 · Autophagy
Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
Soon‐Tae Lee, Hesham Abboud, Sarosh R. Irani, Hideto Nakajima, Amanda L. Piquet, Sean Joseph Pittock, E. Ann Yeh, Jiawei Wang, Sharmila Rajan, James R. Overell et al. · 2024 · Frontiers in Neurology
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
Anna De Lucia, Lucia Mazzotti, Anna Gaimari, Matteo Zurlo, Roberta Maltoni, Claudio Cerchione, Sara Bravaccini, Angelo Delmonte, Lucio Crinò, Patricia Borges de Souza et al. · 2025 · Frontiers in Immunology
Bioinformatory‐assisted analysis of next‐generation sequencing data for precision medicine in pancreatic cancer
Linnéa Malgerud, Johan Lindberg, Valtteri Wirta, Maria Gustafsson‐Liljefors, Masoud Karimi, Carlos Fernández Moro, Katrin Stecker, Alexander Picker, Carolin Huelsewig, Martin Stein et al. · 2017 · Molecular Oncology
Emerging Targets in Advanced Non-Small-Cell Lung Cancer
Francesco Valentino, Gloria Borra, Paolo Allione, Lorena Rossi · 2018 · Future Oncology
Targeted Therapies for the Treatment of Glioblastoma in Adults
Ding Fang Chuang, Xuling Lin · 2019 · Current Oncology Reports
The evolution of pleomorphic xanthoastrocytoma: from genesis to molecular alterations and mimics
Swati Mahajan, Iman Dandapath, Ajay Kumar Garg, Mehar Chand Sharma, Vaishali S. Suri, Chitra Sarkar · 2022 · Laboratory Investigation
CD44 In Sarcomas: A Comprehensive Review and Future Perspectives
Enrique Fernández-Tabanera, Raquel M. Melero-Fernández de Mera, Javier Alonso · 2022 · Frontiers in Oncology
BRAF/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it
Ioannis Tsamis, Georgia Gomatou, Stavroula-Porphyria Chachali, Ioannis Panagiotis Trontzas, Vasileios Patriarcheas, Εmmanouil Panagiotou, Elias Alexandros Kotteas · 2022 · Clinical & Translational Oncology
Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator
Albrecht Stenzinger, Brian J. Cuffel, Noman Paracha, Eric Vail, Jesús García‐Foncillas, Clifford S. Goodman, Ulrik Lassen, Gilles Vassal, Sean D. Sullivan · 2023 · The Oncologist
Synthesis and Structure Determination of Substituted Thiazole Derivatives as EGFR/BRAFV600E Dual Inhibitors Endowed with Antiproliferative Activity
Lamya Hamad Al-Wahaibi, Essmat M. El‐Sheref, Alaa A. Hassan, Stefan Bräse, Martin Nieger, Bahaa G. M. Youssif, Mahmoud A. A. Ibrahim, Hendawy Nagaty Tawfeek · 2023 · Pharmaceuticals
Salivary gland carcinoma: Towards a more personalised approach
Layal Rached, Khalil Saleh, Odile Casiraghi, Caroline Even · 2024 · Cancer Treatment Reviews
Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors
Shiraj Sen, Funda Meric‐Bernstam, David S. Hong, Kenneth R. Hess, Vivek Subbiah · 2017 · JNCI Journal of the National Cancer Institute
Colorectal cancer genomics and designing rational trials
Sebastián Mondaca, Rona D. Yaeger · 2018 · Annals of Translational Medicine
Detection of driver mutations in BRAF can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma
Nasr Alrabadi, Natasha Gibson, Kendra L. Curless, Liang Cheng C, Matthew Kuhar, Shaoxiong Chen, Simon J. P. Warren, Ahmed K. Alomari · 2018 · Modern Pathology
Cardiothoracic manifestations of Erdheim-Chester disease
Jeeban P. Das, Lola X. Xie, Christopher C. Riedl, Sara A. Hayes, Michelle S. Ginsberg, Darragh F. Halpenny · 2019 · British Journal of Radiology
Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase
J. Edward van Veen, Michael T. Scherzer, Julia Boshuizen, Mollee Chu, Annie Liu, Allison S. Landman, Shon Green, Christy L. Trejo, Martin McMahon · 2019 · eLife
Innovation in Oncology Drug Development
Matthew Huber, Brian E. Huber · 2019 · Journal of Oncology
Advances in Treatment of Locally Advanced or Metastatic Non–Small Cell Lung Cancer
Nicholas Giustini, Ah‐Reum Jeong, James A. Buturla, Lyudmila A. Bazhenova · 2020 · Clinics in Chest Medicine
Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review
An-Katrien Seghers, Pieter-Jan AR Cuyle, Eric Van Cutsem · 2020 · Targeted Oncology
AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
Rui Ma, Ling Xu, Xiujuan Qu, Xiaofang Che, Ye Zhang, Yibo Fan, Ce Li, Tianshu Guo, Kezuo Hou, Xuejun Hu et al. · 2018 · British Journal of Cancer
Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
Roei David Mazor, Ran Weissman, Judith Luckman, Liran Domachevsky, Eli L. Diamond, Omar Ibrahim Abdel-Wahab, Shirley Shapira, Oshrat Hershkovitz‐Rokah, David Groshar, Ofer Shpilberg · 2020 · Neuro-Oncology Advances
Follicular dendritic cell sarcoma and its response to immune checkpoint inhibitors nivolumab and ipilimumab
Mee-Young Lee, Carolina Bernabe, Daniel C. Ramirez, Robert G. Maki · 2020 · BMJ Case Reports
Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy
Shenthol Sasankan, Lorraine Rebuck, Gloria Darrah, Moises Harari-Turquie, Ian Rabinowitz · 2020 · Case Reports in Oncology
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours
Pilar Garrido, Raquel Hladun, Enrique de Álava, Rosa Maria Alvarez, Francisco José Bautista, Fernando López‐Ríos, Rámón Colomer, Federico Rojo · 2021 · Clinical & Translational Oncology
Isocitrate Dehydrogenase–Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes
Grant A. Wintheiser, Tyler Zemla, Qian Shi, Nguyen Tran, Kritika Prasai, Sri Harsha Tella, Kabir Mody, Daniel Ahn, Mitesh J. Borad, Tanios Bekaii-Saab et al. · 2022 · JCO Precision Oncology
Bayesian Modelling Strategies for Borrowing of Information in Randomised Basket Trials
Luke Ondijo Ouma, Michael J. Grayling, James M. S. Wason, Haiyan Zheng · 2022 · Journal of the Royal Statistical Society Series C (Applied Statistics)
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Rodrigo Motta, Veronica Y Arnao, Sophia Victoria Lozano Ballena, Carlos Aliaga Macha, Miguel Sotelo Lezama, Cristian Pacheco Román, Paola Montenegro Beltran, Alejandro Figueroa Torrejon · 2022 · ecancermedicalscience
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
Yanxin Liu, Changjiang Dong, Xu‐Cheng He, Yamin Shu, Pan Wu, Jian Zou · 2022 · Journal of Pharmacy & Pharmaceutical Sciences
Anaesthesia, analgesia, and cancer outcomes: time to think like oncologists?
Joshua S. Mincer, Donal J. Buggy · 2023 · British Journal of Anaesthesia
Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine
Donald C. Moore, Andrew S Guinigundo · 2023 · Journal of the Advanced Practitioner in Oncology
Design, Synthesis, and Anti-Proliferative Action of Purine/Pteridine-Based Derivatives as Dual Inhibitors of EGFR and BRAFV600E
Samar A. El-Kalyoubi, Hesham A. M. Gomaa, Elshimaa M. N. Abdelhafez, Mohamed A. Ramadan, Fatimah Agili, Bahaa G. M. Youssif · 2023 · Pharmaceuticals
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.
Arpita Desai, Smitha Patiyil Menon, Grace Kho Dy · 2016 · PubMed Central
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations
Tali Ofir Dovrat, Ethan S. Sokol, Garrett Michael Frampton, Eliya K. Shachar, Sharon Pelles, Ravit Geva, Ido Wolf · 2018 · Cancer Biology & Therapy
Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
Vivek Subbiah, Shiraj Sen, Kenneth R. Hess, Filip Jankú, David S. Hong, Soumen Khatua, Daniel D. Karp, Javier Munoz, Gerald Steven Falchook, Roman Groisberg et al. · 2018 · JCO Precision Oncology
Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology
Matthew Dankner · 2018 · JCO Precision Oncology
A Combinatorial Strategy for Targeting BRAF V600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)
Chandrayee Ghosh, Suresh Kumar, Yevgeniya S. Kushchayeva, Kelli Gaskins, Myriem Boufraqech, Darmood Wei, Sudheer Kumar Gara, Lisa Zhang, Yaqin Zhang, Min Shen et al. · 2020 · Clinical Cancer Research
Encorafenib, Binimetinib and Cetuximab Combined Therapy for Patients with BRAFV600E Mutant Metastatic Colorectal Cancer
Sanne C.F.A. Huijberts, Robin M.J.M. van Geel, René Bernards, Jos H. Beijnen, Neeltje Steeghs · 2020 · Future Oncology
High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy
Lynn H. Lee, Christa Krupski, Jason P. Clark, Mark Wunderlich, Robert B. Lorsbach, Michael S. Grimley, Matthew Burwinkel, Adam C. Nelson, Ashish R. Kumar · 2020 · Blood Advances
Histological features of BRAF V600E‐mutant anaplastic thyroid carcinoma
Tiffany Chen, Jochen H. Lorch, Kristine S. Wong, Justine A. Barletta · 2020 · Histopathology
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview
Wenwei Yang, Yongkun Sun · 2021 · OncoTargets and Therapy
Precision oncology: a strategy we were not ready to deploy
Tito Fojo · 2016 · Seminars in Oncology
More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials
Mattia Andreoletti · 2018 · Perspectives in biology and medicine
Current status and perspectives of patient-derived rare cancer models
Tadashi Kondo · 2020 · Human Cell
Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review
Nishant Munugala, Shishir Kumar Maithel, Rachna T. Shroff · 2021 · HepatoBiliary Surgery and Nutrition
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial
Zhan Wang, Bao‐Dong Qin, Chen-Yang Ye, Miaomiao Wang, Lingyan Yuan, Wei-Ping Dai, Sun Li, Ke Liu, Wenxing Qin, Xiao‐Dong Jiao et al. · 2022 · European Journal of Cancer
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework
Peter J. Murphy, David Glynn, Sofia Dias, Robert M. Hodgson, Lindsay Claxton, Lucy Beresford, Katy L. Cooper, Paul Tappenden, Kate Ennis, Alessandro Grosso et al. · 2021 · Health Technology Assessment
Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies
Deepak Bhamidipati, Vivek Subbiah · 2022 · Trends in cancer
Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
Xuemin Gao, Jian Li, Xinxin Cao · 2022 · Cell Communication and Signaling
Target therapy forBRAFmutated anaplastic thyroid cancer: a clinical and molecular study
Tiago Silva, Ricardo Rodrigues, Ana Saramago, Carolina Pires, Miguel Rito, Mariana Horta, Carmo Martins, Valeriano Alberto Pais Horta Leite, Branca Maria Cavaco · 2023 · European Journal of Endocrinology
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer
Michel Pierre Ducreux, Josep M. Tabernero, Axel F. Grothey, Dirk Arnold, Peter James O'Dwyer, Frank Gilberg, Alexander R. Abbas, Meghna Das Thakur, Hen Prizant, Natsumi Irahara et al. · 2023 · European Journal of Cancer
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
Semir Vranić, Gargi Dan Basu, David W. Hall, Zoran Gatalica · 2023 · Acta Medica Academica
Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype
Marianna Aprile, Simona Cataldi, Caterina Perfetto, Antonio Federico, Alfredo Ciccodicola, Valerio Costa · 2023 · British Journal of Cancer
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Aurélie Swalduz, Michèle Beau‐Faller, David Planchard, Julien Mazières, Sophie Bayle-Bleuez, Didier Debieuvre, Vincent Fallet, Margaux Geier, Alexis Benjamin Cortot, S. Couraud et al. · 2024 · Lung Cancer
Thyroid Gland Malignancies
Maria E. Cabanillas, Ramona Dadu, Mimi I-Nan Hu, Charles S. Lu, G. Brandon Gunn, Elizabeth Gardner Grubbs, Stephen Yenzen Lai, Michelle D. Williams · 2015 · Hematology/Oncology Clinics of North America
Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies
Katsutoshi Oda, Yuji Ikeda, Tomoko Kashiyama, Aki Miyasaka, Kanako Inaba, Tomohiko Fukuda, Kayo Asada, Kenbun Sone, Osamu Wada‐Hiraike, Kei Kawana et al. · 2016 · Journal of obstetrics and gynaecology research
Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project
Andreas Seeber, Guenther A. Gastl, Christian Ensinger, Gilbert Spizzo, Wolfgang Willenbacher, Florian Kocher, Christoph Leitner, Ella Willenbacher, Arno Amann, Normann Steiner et al. · 2016 · Genes & Cancer
Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms
Neval Özkaya, Ahmet Doǧan, Omar Ibrahim Abdel-Wahab · 2017 · Hematology/Oncology Clinics of North America
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
Alberto A. Mendivil, Paul Tung, Randy D. Bohart, Karen A. Bechtol, Bram H. Goldstein · 2018 · Gynecologic Oncology Reports
Exploiting rare driver mutations for precision cancer medicine
Claudia Scholl, Stefan Fröhling · 2019 · Current Opinion in Genetics & Development
The Status and Impact of Clinical Tumor Genome Sequencing
Kenna R Mills Shaw, Anirban Maitra · 2019 · Annual Review of Genomics and Human Genetics
Biliary tract cancer prognostic and predictive genomics
Sebastián Mondaca, Bruno Nervi, Mauricio P. Pinto, Ghassan K. Abou‐Alfa · 2019 · Chinese Clinical Oncology
Systemic treatment options for advanced biliary tract carcinoma
Changqing Xie, Nicole McGrath, Cecilia Monge Bonilla, Jianyang Fu · 2020 · Journal of Gastroenterology
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Raghav Sundar, Maxime Chénard-Poirier, Dearbhaile Catherine Collins, Timothy A. Yap · 2017 · Frontiers in Medicine
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel
Rushabh Gujarathi, Supriya Peshin, Xuchen Zhang, Melinda Bachini, Molly N. Meeks, Rachna T. Shroff, Anjana Pillai · 2025 · Hepatology Communications
Low‐grade serous ovarian carcinoma: A comprehensive literature review
Elizabeth A Goulding, Bryony J. Simcock, Jennifer McLachlan, Rachael van der Griend, Peter H. Sykes · 2019 · Australian and New Zealand Journal of Obstetrics and Gynaecology
Patterns of care for older patients with stage IV non‐small cell lung cancer in the immunotherapy era
Kenneth L. Kehl, Michael J. Hassett, Deborah Schrag · 2020 · Cancer Medicine
Artificial Intelligence in Oncology Drug Discovery and Development
John W. Cassidy, Belle Taylor · 2020 · IntechOpen eBooks
Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer
Yuzhen Yin, Hui Yang, Zhuo Liu, Jie Tan, Chunrong Zhu, Min‐Bin Chen, Rengui Zhou, Lei Wang, Jun Qian · 2020 · Cancer Management and Research
Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
Francesca Ragusa, Silvia Martina Ferrari, Giusy Elia, Sabrina Rosaria Paparo, Eugenia Balestri, Chiara Botrini, Armando Patrizio, Valeria Mazzi, Giovanni Guglielmi, Rudy Foddis et al. · 2022 · International Journal of Molecular Sciences
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer
Oriol Mirallas, D. López-Valbuena, David García-Illescas, Carles Fabregat-Franco, Helena Verdaguer, Josep M. Tabernero, Teresa Mercade Macarulla · 2022 · ESMO Open
Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma
Eva Colic, Preya U. Patel, Oliver A. Kent · 2022 · OncoTargets and Therapy
Developing SHP2-based combination therapy for KRAS-amplified cancer
Tianxia Li, Osamu Kikuchi, Jin Rong Zhou, Yichen Wang, Babita Pokharel, Klavdija Bastl, Prafulla C. Gokhale, Aine Knott, Yanxi Zhang, John G. Doench et al. · 2023 · JCI Insight
Design and synthesis of new quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases
Aliaa M. Mohassab, Heba A. Hassan, Hesham A. Abou‐Zied, Mikako Fujita, Masami Otsuka, Hesham A. M. Gomaa, Bahaa G. M. Youssif, Mohamed Abdel‐Aziz · 2023 · Journal of Molecular Structure
Anaplastic thyroid cancer: Pathogenesis, prognostic factors and genetic landscape (Review)
Abdulmohsen Alhejaily, Omar Alhuzim, Yazeed Alwelaie · 2023 · Molecular and Clinical Oncology
Integrated patient and tumor genetic testing for individualized cancer therapy
Daniel L. Hertz, HL McLeod · 2015 · Clinical Pharmacology & Therapeutics
Effect of Immunotherapy Status on Outcomes in Patients With Metastatic Melanoma to the Spine
Ganesh M. Shankar, Bryan D. Choi, Benjamin L. Grannan, Kevin S. Oh, John H. Shin · 2016 · Spine
Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016
Paul A. Bunn · 2017 · Journal of Clinical Oncology
Next frontiers in systemic therapy for soft tissue sarcoma
Cheuh-Chuan Yen, Tom Wei‐Wu Chen · 2018 · Chinese Clinical Oncology
Mouse Models as a Tool for Understanding Progression in BrafV600E-Driven Thyroid Cancers
Iñigo Landa, Jeffrey A. Knauf · 2019 · Endocrinology and Metabolism
IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma
Siao Ting Chong, Khee Ming Tan, Catherine Y.L. Kok, Shou Ping Guan, Siang Hui Lai, Cindy Lim, Jiancheng Hu, Charles D. Sturgis, Charis Eng, Paula Yeng Po Lam et al. · 2019 · The Journal of Clinical Endocrinology & Metabolism